|
Market Closed -
Nasdaq Stockholm
16:30:00 30/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.600 SEK | +2.86% |
|
+7.78% | +144.90% |
Company Valuation: Sprint Bioscience AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 191.1 | 22.03 | 121.1 | 110.5 | 155.1 | 379.9 | - |
| Change | - | -88.47% | 449.78% | -8.82% | 40.43% | 144.9% | - |
| Enterprise Value (EV) | 120.4 | -7.459 | 71.2 | 85.4 | 155.1 | 379.9 | 379.9 |
| Change | - | -106.19% | 1,054.57% | 19.94% | 81.63% | 144.9% | 0% |
| P/E | -5.64x | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.44x | 265x | 2.4x | 1.68x | 0.93x | 4.38x | 3.92x |
| EV / Revenue | 0x | -0x | 0x | 0x | 0x | 4.38x | 3.92x |
| EV / EBITDA | -0x | 0x | -0x | -0x | 0x | 14.2x | 9.87x |
| EV / EBIT | -0x | 0x | -0x | -0x | 0x | 14.8x | 10.1x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.85 | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 35.11 | 0.083 | 50.48 | 65.64 | 167.2 | 86.8 | 96.8 |
| EBITDA 1 | -25.04 | -60.12 | -0.398 | -18.71 | 98.36 | 26.8 | 38.5 |
| EBIT 1 | -25.63 | -60.74 | -0.845 | -19.67 | 97.29 | 25.7 | 37.5 |
| Net income | -25.08 | - | - | - | - | - | - |
| Net Debt | -70.64 | -29.49 | -49.93 | -25.06 | - | - | - |
| Reference price 2 | 4.795 | 0.553 | 1.735 | 1.582 | 1.470 | 3.600 | 3.600 |
| Nbr of stocks (in thousands) | 39,844 | 39,844 | 69,820 | 69,820 | 105,516 | 105,516 | - |
| Announcement Date | 16/02/22 | 15/02/23 | 14/02/24 | 12/02/25 | 11/02/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 38.67M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 18.13x | 28.02x | 6.57x | 0.34% | 39.44B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRINT Stock
- Valuation Sprint Bioscience AB
Select your edition
All financial news and data tailored to specific country editions
